A recent research featured by Oncotarget has revealed that an aggressive breast cancer cell, which has estrogen receptor beta (Erβ), specific proteins can respond to hormone therapy. Most breast cancer cells contain diverse estrogen or progesterone hormone receptors that enhance normal breast functioning and growth. Aggressive cancer type such as triple negative breast cancer (TNBC), lacks specific receptor proteins, which secure estrogen and progesterone hormones preshent on normal breast cells. When these receptors are absent, these cancers are resistant to the hormone treatment administered. Patients with TNBC have poor prediction due to the likelihood of cancer spreading to other organs. Watch this video on Youtube.
Findings from a research conducted by Mayo Clinic Minnesota revealed that growth of TNB cells lacking estrogen receptor alpha (Erα) but have estrogen receptor beta (ERβ), can be subsided by being treated with estrogen or estrogen-like chemicals. They also noted that patients with TNBC with Erβ and lack Erα, have higher survival rate and a higher likelihood to become cancer free. After further evaluations, Erβ activation drugs may be designed in future to provide therapeutic benefits to such patients.
Oncotarget Travel Sponsorships.
Oncotarget is an oncology peer-reviewed research journal that is committed to maximizing the dissemination of scientific research. Towards the end of 2017, Oncotarget gave travel grants to four biomedical researchers, enabling them to attend the conference on Frontiers in Cancer Science 2017, which was held in November in Singapore. Through these travel sponsorships, the discussion about cancer discoveries was motivated to take place. Check Oncotarget journal at scimagojr.com
As stated by the editor-in-chief of Oncotarget, Mikhail Blagosklonny, Oncotarget has in their heart the desire to see scientific advances spread across the globe to improve understanding and stimulate future findings. With top experts in cancer from all over the world, being the attendees of the Frontiers in Cancer Science, it was the pride of Oncotarget to provide the four international institutions a chance to share their new research there.
The four researchers were; Mohd Anas Shansi, Rajna Kumari, Ruhi Sandeep Deshmukh, and Vladan Milosevic, all presenting research on different topics.
The success of Oncotarget has prompted us to launch sections beyond oncology – https://t.co/ccRO4O68Oj
— Oncotarget (@OncotargetJrnl) December 14, 2017
More About Oncotarget
The oncotarget was first established in 2010. It covers all oncological researches, though it has subsections of other medical topics. They have two open access publications, published by Impact Journals on weekly basis.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/